Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
本文は利用できません。元の情報源をご確認ください。
Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'